Europe
The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.
Almirall, headquartered in Barcelona, Spain, announced it is buying five dermatology products from Allergan. Those include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide) and Seysara (sarecycline).
Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.
Allergan is suing Pfizer over morphine-based opioid drugs, Kadian, that Allergan acquired in December 2008. Read more if you wish to know more about this matter.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
As Britain’s “Brexit” from the European Union moves closer and closer, the European Medicines Agency (EMA), the equivalent to the U.S. Food and Drug Administration (FDA), temporary halted some of its activities in preparation.
Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.
London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, OrbiMed and Brace Pharma Capital.
For its second-quarter financial report, Paris-based Sanofi reported a decrease in net sales for the quarter of 5.7 percent, down to 8.176 billion euros. Sanofi’s diabetes and cardiovascular franchises have struggled in the U.S.
Active Biotech, based in Lund, Sweden, announced that its laquinimod failed to meet its primary endpoint in its Phase II clinical trial for Huntington’s disease.
PRESS RELEASES